CSIMarket Company Name, Ticker, Industry, else..
 
Vistagen Therapeutics Inc   (NASDAQ: VTGN)
Other Ticker:  
 
 
Price: $2.7200 $-0.10 -3.375%
Day's High: $2.85 Week Perf: -2.51 %
Day's Low: $ 2.71 30 Day Perf: -8.42 %
Volume (M): 57 52 Wk High: $ 5.74
Volume (M$): $ 156 52 Wk Avg: $3.41
Open: $2.81 52 Wk Low: $2.22



 Market Capitalization (Millions $) 84
 Shares Outstanding (Millions) 31
 Employees 31
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -47
 Cash Flow (TTM) (Millions $) -52
 Capital Exp. (TTM) (Millions $) 0

Vistagen Therapeutics Inc
Vistagen Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative therapies for mental health disorders. The company focuses on addressing the significant unmet medical needs in the field of psychiatry by utilizing a unique approach called pharmacological stress system modulation. Vistagen's aim is to develop safe and effective treatments for a variety of mental health conditions, including depression, anxiety, and substance use disorders. The company is dedicated to advancing the understanding of these disorders and improving the lives of patients through their cutting-edge therapeutic solutions.


   Company Address: 343 Allerton Avenue South San Francisco 94080 CA
   Company Phone Number: 577-3600   Stock Exchange / Ticker: NASDAQ VTGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.87% 
ALKS        2.78% 
AMLX   -4.22%    
BMRN        1.5% 
LLY        0.07% 
PFE        2.39% 
• View Complete Report
   



Business Update

Pioneering Intranasal Therapies Vistagens Innovative Approach to Social Anxiety Disorder Treatment,

Published Tue, Nov 5 2024 1:36 PM UTC

Exploring New Frontiers in the Treatment of Social Anxiety Disorder: Vistagen s Focus on Intranasal Pherine Therapies In the complex and evolving landscape of mental health treatment, Social Anxiety Disorder (SAD) remains a notable challenge, characterized by significant emotional distress stemming from public and social interactions. Recent discourse in the scientific commu...
Business Update

Vistagen Therapeutics Advancements in Neuroscience and Corporate Developments in Mental Health

Published Fri, Nov 1 2024 2:12 PM UTC

Vistagen Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, is actively engaged in the development of innovative therapies for psychiatric and neurological disorders. As part of its commitment to pioneering neuroscience applications, Vistagen utilizes nose-to-brain neurocircuitry to enhance drug delivery directly to the central nervous sys...
Business Update

Vistagen Launches Hopeful New Phase 3 Trial for Fasedienol A Game Changer in the Battle Against Social Anxiety D...

Published Mon, Sep 23 2024 1:47 PM UTC

In a significant advancement for mental health treatment, Vistagen Therapeutics, a neuroscience-focused biopharmaceutical company based in South San Francisco, has announced the commencement of its PALISADE-4 Phase 3 clinical trial for fasedienol. This investigational neuroactive pharmaceutical, delivered via nasal spray, aims to provide a new therapeutic option for individu...
Business Update

Vistagens Strive for Innovation Expanding Intellectual Property and Positive Results in Mental Health Therapies ...

Published Tue, Jul 9 2024 3:47 PM UTC

Vistagen Expands Global Intellectual Property Portfolio with New Patents for Migraine Treatment and Reports Positive Results for PH15 StudyVistagen, a clinical-stage neuroscience-focused biopharmaceutical company, has recently broadened its global intellectual property portfolio by obtaining new patents related to the use of PH80 in treating migraines. PH80 is a non-systemi...
Business Update

Vistagen Achieves Impressive Fiscal Year 2024 Results and Unveils Promising Neurocircuitry Therapies for Mental Healt...

Published Wed, Jun 12 2024 12:54 AM UTC

SOUTH SAN FRANCISCO, Calif. - Vistagen (Nasdaq: VTGN), the neuroscience-focused biopharmaceutical company, celebrated a year of extraordinary achievements as it recently announced its fiscal year 2024 financial results and provided an encouraging corporate update. Vistagen s unwavering dedication to developing groundbreaking therapies for psychiatric and neurological disorde...






Vistagen Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com